Abstract
Identifying patients for whom the treatment is effective is an absolute necessity regarding the effectiveness of their care and ethics and avoiding them from losing opportunities and unnecessary adverse effects. It is also an economic necessity due to the very high cost of new treatments called “expensive molecules”, in particular immunotherapy, which poses problems of access to these treatments and constitutes a real financial challenge for health systems. In clinical routine as in research, imaging is the essential tool for deciding the success or failure of treatment, with a major medico-economic impact if we consider that these very expensive treatments are only effective in a fraction of patients and that they do not always bring a major benefit.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
